Reviews of Cabot Investing Advice and Advisories

Cabot Investing Advice reviewed by our subscribers:

Cabot Analysts
We are always happy to get feedback from our customers—here’s what they have to say. Click the links to see reviews of individual newsletters and for general reviews of Cabot Investing Advice and our advisories.

Cabot Investing Advice Reviews

General reviews from subscribers to one or more Cabot advisories»

Cabot Benjamin Graham Value Investor Reviews

Reviews from subscribers to Cabot Benjamin Graham Value Investor»

Cabot Dividend Investor Reviews

Reviews from subscribers to Cabot Dividend Investor»

Cabot Growth Investor Reviews

Reviews from subscribers to Cabot Growth Investor»

Reviews of the Cabot Investors Conference

Reviews from recent Cabot Investors Conference attendees»

Cabot's Low-Priced Stock Report

Reviews of the annual special report, Cabot's Low-Priced Stock Report»

Cabot Options Trader Reviews

Reviews from subscribers to Cabot Option Trader and Cabot Option Trader Pro»

Cabot Small-Cap Confidential Reviews

Reviews from subscribers to Cabot Small-Cap Confidential»

Cabot Top Ten Trader Reviews

Reviews from subscribers to Cabot Top Ten Trader»

Cabot Wealth Advisory Reviews

Reviews from subscribers to Cabot Wealth Advisory, Cabot's free advisory»

Cabot China & Emerging Markets Report Reviews

Reviews from subscribers to Cabot China & Emerging Markets Report»

Cabot Stock of the Month Reviews

Reviews from subscribers to Cabot Stock of the Month»

Stock Picks

Ross Stores

McKesson (MCK) distributes ethical and proprietary drugs, surgical supplies and health and beauty products throughout North America to the healthcare industry. The company also provides technical consulting services to biotech and pharmaceutical manufacturers.

Carnival Cruise Lines

Having just returned from vacation, Tim Lutts is thinking of the millions of baby-boomers who are spending more and more money on leisure travel, particularly on cruises, an industry that is dominated by a few big players.

China Biologic Products

Paul Goodwin advises putting this stock on your watch list.

Cabot Wealth Advisory

Beach Weather in the Market

By Paul Goodwin on July 31, 2015

It’s the beginning of August, high summer in New England, and a bit of summer fatigue is setting in. Summer in New England is short, so we try to pack half a year’s worth of cookouts, beach days, hikes, kayaking, sight-seeing and other outside recreation into three months. It’s fun, but the pace can be a bit frantic, especially as the season enters its third act. Frankly, all I want to do now is lie on a beach somewhere and read a book. Read More >

Managing Your Stock Portfolio to the Market's Tune

By Michael Cintolo on July 30, 2015

In today’s Wealth Advisory, I’m doing something I’ve never done before—reprinting an entire piece I wrote in Cabot Growth Investor last Wednesday. It doesn’t involve any specific stock advice (that is and always will be for subscribers only), but it details the wild divergences in the market (which are now getting lots of press—even the Wall Street Journal had a big write-up on it Monday), what it means, and how I’m advising people to handle it—I think it’s very timely.Read More >

Do Your Stocks Have Borrowing Trouble?

By Nancy Zambell on July 28, 2015

Hostess is making news today as it is issuing $1.23 million in term loans—most of which will go toward paying $905 million in a special dividend to its private shareholders—which I may add, is also more than two times what the buyers paid for this tasty snack business, and triples the company’s debt. According to Bloomberg, these types of deals grew to nearly $16 billion in the second quarter, the highest level in the past 12 months. I’m not making a judgment for or against this action. I just want to make a point that this debt, or leverage recapitalization—spurred by low interest rates—is increasingly becoming a method in which private equity holders get their money back—without selling the business. But it does burden the company with additional debt, which isn’t going to fund company expansion or operations.Read More >